Pulmonary Fibrosis Foundation's Global Dinner Raises Funds and Awareness For
The Fight Against Pulmonary Fibrosis
CHICAGO, Oct. 17, 2012
Breathe Benefit 2012 Honors Co-Founder and Acknowledges Grant Recipients
CHICAGO, Oct. 17, 2012 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis
Foundation's (PFF) annual dinner, Breathe Benefit 2012: Community Inspiring a
Cure, was held on Saturday, October 13, 2012, and raised over $150,000. The
money will be used to support the goals of the Foundation's mission which
include finding a cure for idiopathic pulmonary fibrosis (IPF), advocating for
the pulmonary fibrosis (PF) community, promoting disease awareness, and
providing a compassionate environment for patients and their families.
In order to include the national and international pulmonary fibrosis
community, the Foundation coordinated "Global Dinners" and other fundraising
events throughout the world. Over 25 "Global Dinners" were held across the
United States and in the European Union. "These events fostered a greater
sense of community with our patients, families, and friends while recognizing
the efforts of those who work tirelessly to support the Foundation's mission,"
stated Patti Tuomey, Chief Operating Officer. "We thank everyone who
participated in the Breathe Benefit 2012 in Chicago and around the world."
The Drake Hotel's Grand Ballroom was the setting for the inspirational Chicago
Dinner.Over 240 individuals attended the event. Dinner guests included
patients, caregivers, family members, researchers, medical professionals, and
other valued supporters of the PFF. For the second year, the Foundation was
honored to have Mary Ann Ahern from NBC5 News emcee the evening. She and her
husband Tom Ahern also served as honorary chairs for the event. Co-chairs of
the dinner were Kathy Petrak and Chuck Lawless. "I'm honored to have
co-chaired the PFF's Breathe Benefit this year with my good friend Kathy
Petrak," said Chuck Lawless of Mesirow Financial. "It's been eye-opening to
meet the patients and families and learn about my own personal friends and
clients who have family members afflicted with this disease." Kathy Petrak,
longtime friend of the Foundation who has held many successful fundraisers for
the PFF, said about the evening, "We are grateful for the support and hard
work of so many people in making the Breathe Benefit 2012 a tremendous
success. We would like to thank the honorary chairs, the dinner committee, and
silent auction donors for their time and generosity."
The evening featured a special photographic tribute to one of the Foundation's
founders, I.M. Rosenzweig, Ph.D. His daughter, Karen Schwartz, and the PFF's
President and CEO, Daniel M. Rose, MD, provided a touching and moving
remembrance of Dr. Rosenzweig. Mike, as he was known to most, lost his
courageous battle to idiopathic pulmonary fibrosis on June 23, 2012.23 Dr.
Rosenzweig and his brother Albert Rose, both having been diagnosed with the
disease and previously having lost a sister to IPF, started the Foundation in
September of 2000. Albert Rose succumbed to IPF in 2002. Dr. Rosenzweig
tirelessly led the Foundation until progression of his disease forced him to
retire in 2009. In recognition of Dr. Rosenzweig and his dedication to funding
research, the Young Investigator Awards have been re-named in his honor.
The Foundation presented awards to recognize significant contributions to the
PF community. Longstanding Foundation advocate, Charles P. McQuaid, was given
the "Legacy Award" for his continued guidance and support of the Foundation's
mission. Booz Allen Hamilton was honored with the "Impact Award" for
generously lending staff time and expertise in helping develop a business plan
for the creation and implementation of a Care Center Network and Pulmonary
Fibrosis Patient Registry. Carl Salzano, Senior Vice President at Booz Allen
Hamilton and member of the PFF's Board of Directors, accepted the award on
behalf of his company. Daniel M. Rose, MD, noting the award recipients said,
"The Foundation is thankful to have the opportunity to honor Mr. McQuaid and
Booz Allen Hamilton. Their support and commitment to our mission has been
instrumental in making the Foundation the leading pulmonary fibrosis patient
advocacy organization in the world and in positioning us for even greater
impact and reach."
The evening's program also recognized the 2012 PFF Research Fund's award
recipients. The awards were presented by Kevin K. Brown, MD, member of the
Foundation's Board of Directors and chairman of the Medical Advisory Board.
The I.M. Rosenzweig Young Investigator Awards were presented to Haitao (Mark)
Ji, Ph.D., and to Rebecca Keith, MD. Established Investigator Awards were
presented to James S. Hagood, MD, and Glenn Rosen, MD. The Foundation
gratefully acknowledges the support from InterMune, Inc. (Brisbane, CA) for
funding an I.M. Rosenzweig Young Investigator Award and to Boehringer
Ingelheim (Ridgefield, CT) for funding the Established Investigator Award.
Additionally, the Foundation announced the six recipients of the 2012 Leanne
Storch Support Group Fund grants.
Adding to the excitement of the evening were the emotional, personal stories
told by award-winning Broadway actress and devoted PFF advocate Julie Halston
and her husband, broadcaster Ralph Howard, a PF patient and lung transplant
recipient. The couple, after being touched by the disease a second time when
they lost a close friend to PF, Broadway critic Michael Kuchwara, now organize
a PFF signature event, Broadway Belts for PFF! The event has raised over
$90,000 in its first two years; the next Broadway Belts for PFF! will be held
on February 25, 2013.
"On behalf of the Foundation and the PF community I would like to thank the
individual and corporate sponsors for their generosity," stated Daniel M.
Rose, MD. Sponsors included: Alan and Pam Schwed; Boehringer Ingelheim; BSGI;
The Buchanan Family; Chuck and Jennifer Lawless; Chuck and Monica McQuaid; The
Culliton-Metzger Family; Daniel M. Rose, MD; Don Luken and Friends; Jennifer
A. Galvin, MD; Jenny H. Krauss and Otto F. Krauss Charitable Foundation Trust;
John Hancock; Lawless Advisory Group at Mesirow Financial; Mark Fuller and
Family; Manny and Brian Millman, Shelle Jewelers; The McMahon Family; Michael
P. Savoca Memorial Foundation; Panoplos Advisory Group at Mesirow Financial;
Patti Tuomey and Chris Martin; The Petrak Family in Memory of Bill Pacella;
Petrak Industries; Phyllis N. Demont; Rick and Krista Meyers; RS Family Trust,
DTD; Sandra Kully; Trey Schwab; University of Wisconsin Health; and the
University of Wisconsin Transplant Program.
About the Pulmonary Fibrosis Foundation
The mission of the Pulmonary Fibrosis Foundation (PFF) is to help find a cure
for idiopathic pulmonary fibrosis (IPF), advocate for the pulmonary fibrosis
community, promote disease awareness, and provide a compassionate environment
for patients and their families. The PFF collaborates with physicians,
organizations, patients, and caregivers worldwide. December 1-3, 2011 the PFF
hosted its first biennial international scientific conference, IPF Summit
2011: From Bench to Bedside, in Chicago; PFF Summit 2013 will be held December
5–7, 2013. For more information visit www.pulmonaryfibrosis.org or call
About Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a condition in which over a period of
time the lung tissue becomes thickened, stiff, and scarred. The development of
the scar tissue is called fibrosis. As the lung tissue becomes scarred and
thicker, the lungs lose their ability to transfer oxygen into the bloodstream.
As a result, the brain and other organs don't receive the oxygen they need. In
some cases, doctors can determine the cause of the fibrosis, but in most
cases, there is not a known cause. When there is no known etiology for the
fibrosis (and certain pathologic or radiographic criteria are met), the
disease is called idiopathic pulmonary fibrosis, or IPF. IPF affects
approximately 200,000 individuals in the United States (US), and 138,000
individuals in the European Union (EU). The annual mortality is estimated to
be 40,000 in the US alone, with an average survival of 2–3 years following
diagnosis. There is no cure for IPF. There is no FDA-approved treatment for
IPF in the US and limited therapeutic options available for individuals with
mild-to-moderate IPF in the EU, Canada, and Asia.
Associate Vice President, Communications and Marketing
SOURCE The Pulmonary Fibrosis Foundation
Press spacebar to pause and continue. Press esc to stop.